Navigation Links
Jazz Pharmaceuticals to Report 2014 Second Quarter Financial Results on August 5, 2014
Date:7/22/2014

DUBLIN, July 22, 2014 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2014 second quarter financial results on Tuesday, August 5, 2014, after the close of the financial markets.  Company management will host a live audio webcast immediately following the announcement at 4:30 p.m. EDT/9:30 p.m. IST to provide a business and financial update and discuss second quarter 2014 financial results.

Interested parties may access the live audio webcast via the Investors & Media section of the Jazz Pharmaceuticals website at www.jazzpharmaceuticals.com.  Please connect to the website prior to the start of the conference call to ensure adequate time for any software downloads that may be necessary to listen to the webcast.  A replay of the webcast will be archived on the website for one week.

Audio webcast/conference call:
U.S. Dial-In Number:  +1 866 277 1184
International Dial-In Number: +1 617 597 5360
Passcode: 29980973

A replay of the conference call will be available through August 12, 2014 and accessible through one of the following telephone numbers and entering the passcode:

Replay U.S. Dial-In Number: +1 888 286 8010
Replay International Dial-In Number:  +1 617 801 6888
Passcode: 13741471

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc is a specialty biopharmaceutical company focused on improving patients' lives by identifying, developing and commercializing differentiated products that address unmet medical needs.  The company has a diverse portfolio of products and/or product candidates in the areas of sleep, hematology/oncology, pain and psychiatry.   The company's U.S. marketed products in these areas include: Xyrem® (sodium oxybate) oral solution, Erwinaze® (asparaginase Erwinia chrysanthemi), Prialt® (ziconotide) intrathecal infusion, Versacloz® (clozapine) oral suspension, FazaClo® (clozapine, USP) HD and FazaClo LD.  Jazz Pharmaceuticals also has a number of products marketed outside the U.S., including Erwinase® and Defitelio® (defibrotide).  For more information, please visit www.jazzpharmaceuticals.com.


'/>"/>
SOURCE Jazz Pharmaceuticals plc
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
2. Auxilium Pharmaceuticals to Present at the Deutsche Bank 37th Annual Healthcare Conference
3. Nouveau Life Pharmaceuticals (HRID) Contracts with U.S. Manufacturer to Produce New Female Supplement
4. BioElectronics Survey Indicates a Five-Fold Superior Pain Relief Compared to OTC Pharmaceuticals
5. Icahn Issues Statement Regarding Amylin Pharmaceuticals
6. Almost 50 Percent of the Glaucoma Patient Population Remains Untreated, Signifying a Vast Market for Glaucoma Pharmaceuticals, Finds Frost & Sullivan
7. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
8. Onyx Pharmaceuticals Announces FDA Advisory Committee to Review Carfilzomib for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
9. Jazz Pharmaceuticals Announces First Quarter 2012 Financial Results Conference Call On May 8, 2012
10. Inovio Pharmaceuticals Granted U.S. Patent Protection for Synthetic Vaccine for Cervical Dysplasia and Cancer
11. Avanir Pharmaceuticals To Present at Three Conferences In May
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/28/2017)... , Feb 28, 2017 Nordic Nanovector ASA ... year 2016. A presentation of the results by the company,s senior ... Oslo - details below. ... 2016 was a very successful year ... clinical development of Betalutin®, progressed with our preclinical candidates and build ...
(Date:2/27/2017)... Health, Inc. (NYSE: HYH ) today reported fourth ... and related key planning assumptions. Executive Summary 2016 ... increase compared to the prior year. Net ... to net income of $15 million in the fourth quarter ... compared to adjusted net income of $27 million in the ...
(Date:2/27/2017)... , Feb. 27, 2017  International Biophysics Corporation, a ... , today announced a 34% revenue growth in 2016 ... increase in unit sales.  This growth was fueled by its ... in addition to the expansion of its global sales of ... International Biophysics, CEO, "As we enter our 25 th ...
Breaking Medicine Technology:
(Date:2/27/2017)... ... February 27, 2017 , ... Anahata Ananda of ... is happy to announce her “Spring Rejuvenation in Sedona” personally tailored retreats. ... retreats offer the winter-weary soul an excellent opportunity to come out of hibernation ...
(Date:2/27/2017)... ... ... Carothers is not your typical author. She went from working as a movie extra on ... God, when she isn’t swimming as a performing mermaid. , Her book isn’t typical either. ... offers a comedic look at the dysfunctions of God’s family, before Lucifer was sent to ...
(Date:2/27/2017)... (PRWEB) , ... February 26, 2017 , ... Miro is ... pioneer sound and video system brings songs, movies, TV shows and much more apps ... offers clear, high-definition sound. An immersive view of 1280 x 720 provides crisp images ...
(Date:2/27/2017)... (PRWEB) , ... February 27, 2017 , ... ... rehabilitation and alcohol treatment programs in British Columbia, Canada, at https://www.sunshinecoasthealthcentre.ca/ , ... its team. The new hire, Mackenzie Alsager, showcases the Centre's commitment to innovation ...
(Date:2/27/2017)... Morristown, New Jersey (PRWEB) , ... February 27, 2017 , ... ... the highest cancer rates, among all types and genders. And the need for advanced ... led by RWJ and its top-rated cancer care program, in collaboration with their non-profit ...
Breaking Medicine News(10 mins):